Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Alimera Sciences, Inc. (NASDAQ: ALIM) is a leading global pharmaceutical company committed to advancing retinal health. Founded in June 2003, the company specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Alimera's primary focus is on diseases affecting the retina, particularly those that are not well managed by current therapies. The company's flagship product, ILUVIEN, is a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) outside the U.S.
ILUVIEN utilizes CONTINUOUS MICRODOSING™ technology, releasing sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months. This technology helps to reduce disease recurrence, thereby enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S. and multiple international markets, including 17 European countries, China, and regions in the Middle East.
Recently, Alimera announced positive data from several clinical studies, such as the PALADIN study, which evaluated the long-term safety of ILUVIEN in treating DME. The company also made headlines by completing enrollment for the Synchronicity Study, focusing on YUTIQ, another fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
Moreover, Alimera continues to expand its executive team to strengthen its financial and operational capabilities. Elliot Maltz, C.P.A., has been named as the new Chief Financial Officer to drive growth and improve cash flow. The company's European operations are managed through its subsidiary, Alimera Sciences Limited, based in London.
Financially, Alimera Sciences has shown robust growth. In Q4 2023, the company reported net revenues of $26.3 million, an 88% increase compared to the same period in 2022. For the full year 2023, net revenues were up 49% to $80.8 million. This growth is a testament to the successful commercialization of ILUVIEN and YUTIQ.
Looking ahead, Alimera aims to further its mission of being invaluable to patients, physicians, and partners concerned with retinal health. The company is actively involved in numerous clinical studies and regulatory efforts to expand the therapeutic indications for its products, ensuring continued innovation and improved patient outcomes.
For more information, please visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) presented new data at the American Society of Retina Specialists meeting, revealing significant reductions in treatment burden for Diabetic Macular Edema (DME) patients receiving ILUVIEN. Post-treatment, the percentage of patients needing one or fewer injections per year increased by 3.2 times. Additionally, the need for over four treatments per year decreased by 50%. The findings, shared by Dr. Victor Gonzalez, were derived from 83 eyes observed over two years, supporting Alimera's ongoing NEW DAY Study on ILUVIEN's long-term benefits.
Alimera Sciences (Nasdaq: ALIM) announces that CEO Rick Eiswirth will present at the 23rd Annual H.C. Wainwright Global Investment Conference from September 13-15, 2021. The corporate presentation will be available on September 13 at 7:00 AM ET. Additionally, David Holland, Chief Marketing Officer, and Philip Ashman, Chief Operating Officer, will be available for one-on-one meetings throughout the event. Interested investors can register to attend the conference via the provided link.
On August 24, 2021, Alimera Sciences (NASDAQ: ALIM) announced that its European subsidiary received pricing and reimbursement approval for ILUVIEN® for diabetic macular edema (DME) in Belgium, facilitated by its partner, Horus Pharma S.A.S. This approval marks a strategic expansion of ILUVIEN availability in Europe, aimed at enhancing growth in the Benelux region. ILUVIEN is a sustained-release intravitreal implant designed to treat vision impairment associated with chronic DME and prevent relapse in non-infectious uveitis.
Alimera Sciences reported a consolidated net revenue of $21.7 million for Q2 2021, a remarkable 117% increase from Q2 2020. The company's net income stood at $7.6 million, reversing a loss of $2.5 million last year. Notably, end user demand rose by 16% across key markets. The increase in revenues includes $11.0 million from a licensing agreement with Ocumension Therapeutics, significantly improving the company’s financial position. However, operating expenses increased to $12.9 million as spending normalized post-pandemic.
Alimera Sciences, Inc. (ALIM) announces a conference call on August 13, 2021, at 9:00 AM ET to discuss its Q2 2021 financial results and corporate developments. This call follows the release of financial results before market open on the same day. Participants are encouraged to pre-register for the call, with dial-in options available for those unable to register online.
The company specializes in developing prescription ophthalmic pharmaceuticals, focusing on retinal diseases that impact many aging individuals.
Alimera Sciences Europe Limited has partnered with Tanner Pharma UK Limited to launch a Named Patient Program for ILUVIEN®, focusing on treatment for diabetic macular edema (DME) and non-infectious posterior uveitis (NIU-PS). This program aims to provide access to ILUVIEN where it is not commercially available. ILUVIEN, designed for sustained release of fluocinolone acetonide for up to 36 months, is approved in several countries for DME.
The collaboration underscores Alimera's commitment to improving patient access to innovative ophthalmic therapies.
Alimera Sciences, a pharmaceutical company focused on ophthalmic pharmaceuticals, announced its participation in the Summer Solstice - Best Ideas from the Buy Side Conference from June 1-4, 2021. President and CEO Rick Eiswirth will present on June 2 at 10:30 am ET. The presentation will be available via live webcast.
This virtual conference showcases 35 top ideas from qualified institutional investors, focusing on companies with potential for alpha.
Alimera Sciences (NASDAQ: ALIM) has appointed Dr. David Dyer as chief retina specialist, enhancing its leadership team. Dr. Dyer brings significant experience from his practice in Kansas City and is expected to contribute valuable insights in retina care. His role aims to drive Alimera's vision of being a leader in retinal treatments, particularly focusing on the ILUVIEN product. Additionally, Dr. Dyer's involvement in the Phase 4 NEW DAY Study highlights Alimera's commitment to advancing treatment options. This expansion signals Alimera's intent to strengthen its market position and broaden its global reach.
Alimera Sciences (Nasdaq: ALIM) reported a 23% decline in consolidated net revenue for Q1 2021, totaling approximately $11.2 million. U.S. revenue fell 21% to $5.6 million, reflecting ongoing COVID-19 impacts on patient access. International sales also decreased by 25%. Despite a net loss of $(3.6 million), down from $(1.2 million) in Q1 2020, the company announced a $20 million deal with Ocumension Therapeutics, bolstering its cash position amidst challenges. Management remains optimistic about revenue recovery in Q2 2021.
Alimera Sciences, Inc. (Nasdaq: ALIM) will report its first quarter 2021 financial results on April 28, 2021, after market close. A conference call is scheduled for April 29 at 9:00 AM ET to discuss these results and corporate developments. Participants can pre-register for the call or join via provided dial-in numbers. The call will also be accessible through a live webcast and will have a replay available for 90 days. Alimera specializes in prescription ophthalmic pharmaceuticals targeting retinal diseases.
FAQ
What is the current stock price of Alimera Sciences (ALIM)?
What is the market cap of Alimera Sciences (ALIM)?
What is Alimera Sciences, Inc. specialized in?
What is ILUVIEN?
Where is Alimera Sciences headquartered?
What are the latest financial results for Alimera Sciences?
Who is the new Chief Financial Officer of Alimera Sciences?
What recent clinical studies has Alimera Sciences completed?
In which regions is ILUVIEN approved?
What is the mission of Alimera Sciences?
What technology does ILUVIEN utilize?
Where can I find more information about Alimera Sciences?
